Compare Natera Inc. Common Stock (NTRA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while State Street SPDR S&P Biotech ETF trades at $147.2 (market cap $10.05B). The key difference: Natera Inc. Common Stock is far larger — about 5.7× State Street SPDR S&P Biotech ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| NTRA | XBI | |
|---|---|---|
Market Cap | $57.03B | $10.05B |
Volume | 1,131,157 | 10,367,649 |
Sector | Health | Broad Market / Factor |
52-Week High | $425.64 | $169.55 |
52-Week Low | $179.42 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $56.18B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
